Today: 10 June 2026
Capital One stock sinks nearly 7% after Brex deal and Q4 numbers; what investors watch next
23 January 2026
2 mins read

Capital One stock sinks nearly 7% after Brex deal and Q4 numbers; what investors watch next

NEW YORK, Jan 23, 2026, 14:26 EST — Trading in the regular session.

  • Capital One shares dipped in afternoon trading following the announcement of a $5.15 billion deal to acquire fintech Brex.
  • Investors also grappled with fourth-quarter results revealing a rise in credit-loss provisions alongside a surge in expenses.
  • Next week’s Fed decision is drawing attention from traders focused on rate-sensitive consumer lenders.

Shares of Capital One Financial Corporation dropped 6.8% to $219.17 in Friday afternoon trading, a steep slide by bank-stock norms. The decline followed the company’s announcement of a new fintech acquisition alongside quarterly results showing increased expenses.

The selloff hits Capital One at a tricky point. The bank continues to pour money into integrating its Discover deal, even as it pushes investors to watch capital levels, buybacks, and credit trends in its main card business.

Brex has rolled out a corporate-card and spend-management platform, but it also faces another test in execution. This move comes amid investor jitters over consumer-credit risk and concerns about how rising rates will impact earnings at major card lenders.

A regulatory filing revealed Capital One plans to buy Brex for a total of $5.15 billion, consisting of around $2.75 billion in cash and roughly 10.6 million Capital One shares, though these figures could be adjusted. The deal is pending regulatory approval.

Capital One CEO Richard Fairbank said in a joint statement that the acquisition “accelerates” the bank’s expansion into business payments. Brex CEO Pedro Franceschi added the deal would “supercharge” the company’s next phase, and he plans to stay on as head of the unit if the transaction wraps up by mid-2026. Securities and Exchange Commission

Capital One posted fourth-quarter net income of $2.1 billion, translating to $3.26 per share, with adjusted earnings coming in at $3.86 per share. Total net revenue increased to $15.6 billion. Non-interest expenses edged up to $9.3 billion, while the provision for credit losses climbed to $4.1 billion.

The company reported net interest income of $12.47 billion for the quarter, a sharp rise from $8.10 billion a year ago. Its net interest margin, which gauges the difference between loan earnings and deposit costs, stood at 8.26%.

December’s monthly credit figures revealed a domestic card net charge-off rate sitting at 5.01%, with a 30+ day delinquency rate of 3.99%. These metrics are key indicators of borrower distress.

Analysts were swift to weigh in on the Brex price and its short-term impact. BTIG dropped its Capital One price target to $270 from $308 but maintained a Buy rating. Analyst Vincent Caintic cited “near-term dilution” and a slowdown in share buybacks in the revised forecast. Investing.com

COF’s decline stood out amid a weaker financial sector. American Express dropped roughly 2%, Synchrony Financial lost about 2%, JPMorgan dipped near 2%, and Bank of America slipped around 1.5%.

Capital One’s heavy dependence on credit cards remains its biggest wildcard, especially as the sector faces policy pressure. President Donald Trump has suggested capping credit-card interest rates at 10% for a year. Fairbank cautioned that this move might limit credit availability and ultimately hurt the economy.

The Federal Reserve’s meeting on January 27–28 is next on traders’ radar, with the rate decision set for January 28. Changes in the outlook for short-term rates could quickly impact card yields, funding expenses, and investor appetite for consumer lenders.

Stock Market Today

  • Roche Shares Rise on $2.3 Billion Nurix Cancer Drug Deal
    June 10, 2026, 5:22 AM EDT. Roche Holding Ltd shares rose 1.07% to CHF 322.20 after announcing a $2.3 billion licensing deal with Nurix Therapeutics for the blood-cancer drug bexobrutideg (NX-5948), a BTK degrader targeting chronic lymphocytic leukemia (CLL). Roche will fund 60% of development costs and plans to start Phase 3 trials this summer, aiming for a 2030 launch. The deal includes $700 million upfront and milestone payments. Roche expects the drug to improve efficacy and tolerability over current BTK inhibitors, addressing resistance issues. The collaboration enhances Roche's oncology pipeline amid biosimilar pressures, with the company forecasting mid-single-digit sales growth and strong earnings in 2026. The Swiss Market Index edged up 0.35% amid the news.

Latest articles

Ondas Stock Comes Back Into the Spotlight After 13% Drop; Drone Trade Faces Fresh Challenge

Ondas Dips Premarket After 2.7 Million-Share Filing

10 June 2026
SoFi Technologies traded near $16.47 in early premarket, little changed as investors weighed its AI and digital asset product push against a risk-off market mood, with no fresh earnings news and inflation data looming that could impact rates, loan demand, and fintech valuations.

SoFi Stock Faces a Crucial Pre-Market Test as Wall Street Turns Defensive

10 June 2026
Rolls-Royce shares rebounded 1.5% in London after Tuesday’s 2.68% drop, as investors weighed fresh airline criticism over engine delays against the company’s reaffirmed 2026 profit and cash flow guidance; CEO Tufan Erginbilgic said Rolls had a “strong start to the year,” but risks remain if airline pressure leads to higher costs or slower cash conversion.
LVMH Drops Following Quick Rally, RBC Still Sees Recovery for Luxury

LVMH Drops Following Quick Rally, RBC Still Sees Recovery for Luxury

10 June 2026
LVMH shares slipped 0.49% to €489.90 in Paris after a four-day rebound, as investors weighed RBC’s reiterated Buy rating with a €600 target against ongoing 2026 losses and a 24% year-to-date drop; all eyes now turn to July’s first-half results for signs of recovery in Fashion & Leather Goods and any relief from Middle East weakness.
Roche Shares Edge Up After $2.3 Billion Nurix Cancer Pact

Roche Shares Edge Up After $2.3 Billion Nurix Cancer Pact

10 June 2026
Roche’s participation certificates climbed 1.07% to CHF 322.20 after announcing a $2.3 billion deal with Nurix Therapeutics for late-stage blood-cancer drug bexobrutideg, planned to enter Phase 3 trials this summer in CLL, as investors weigh the asset’s potential to offset losses from expiring patents and drive mid-single-digit sales growth in 2026.
YY Group Shares Jump Premarket on Humanoid Robot Move

YY Group Shares Jump Premarket on Humanoid Robot Move

10 June 2026
YYGH jumped to $0.19 in early pre-market after announcing deployment of Unitree G1 humanoid robots for facility management, aiming to turn operational know-how into higher-margin data assets, but the stock remains volatile near record lows after a recent reverse split and has not confirmed robot-driven revenue or margin gains.
HBAN stock slips as Huntington tees up new debt sale ahead of Cadence deal — what to watch next week
Previous Story

HBAN stock slips as Huntington tees up new debt sale ahead of Cadence deal — what to watch next week

Broadcom stock slides as Intel shock ripples through chips ahead of Fed decision
Next Story

Broadcom stock slides as Intel shock ripples through chips ahead of Fed decision

Go toTop